NCT00153140已完成4 期
Polyethyleneglycol3350 vs Tegaserod in Treatment of Patients With Chronic Constipation
Braintree Laboratories25 个研究点 分布在 1 个国家目标入组 239 人开始时间: 2004年7月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 239
- 试验地点
- 25
- 主要终点
- A successful outcome is defined as no longer meeting the definition of constipation using ROME I criteria
研究概览
简要总结
The purpose of this study is to compare the safety and efficacy of extended polyethyleneglycol3350 use to tegaserod in patients with chronic constipation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female outpatients at least 18 years of age
- •Constipated according to ROME I criteria
- •If female and of childbearing potential, patient must be surgically sterilized or using oral contraceptives, depot contraceptives, double- barrier method, intrauterine device, or testifies that she is monogamous with a vasectomized partner, or practices abstinence and will continue to do so during the duration of study
- •Are otherwise in good health, as judged by a physical examination
- •In the investigator's judgment, patient is mentally competent to sign an instrument of informed consent
排除标准
- •Patients with heme positive stool at screening that is not associated with hemorrhoids or anal fissures.
- •Patients with hypo- or hyperthyroidism as determined by medical history.
- •Patients with severe renal impairment.
- •Patients with moderate or severe hepatic impairment.
- •Patients with known or suspected perforation or obstruction.
- •History of gastric retention, inflammatory bowel disease, bowel resection, or colostomy.
- •Patients with symptomatic gallbladder disease, suspected sphincter of Oddi dysfunction, or abdominal adhesions.
- •Patients with a known history of organic cause for their constipation.
- •Patients currently taking, or planning to take any of the following medications that are known to effect bowel habits:
- •Antidiarrheals
- •Antacids containing magnesium or aluminum salts
- •Anticholinergics
- •Antispasmodic agents
- •Erythromycin and other macrolides
- •Octreotide
- •Lotronex, Zofran, or other 5-HT3 antagonists
- •Zelnorm, or other 5-HT4 agonists
- •Opiods/narcotic analgesics
- •Prokinetics
- •Serotonin re-uptake inhibitors or tricyclic antidepressants
- •Calcium antagonists
- •Patients who are breastfeeding, pregnant, or intend to become pregnant during the study.
- •Female patients of childbearing potential who refuse a pregnancy test.
- •Patients with a known allergy to tegaserod (or any of its excipients) or polyethyleneglycol.
- •Patients who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures.
- •Patients who, within the past 30 days have participated in an investigational clinical study.
- •Patients that have undergone a colonoscopy within 30 days of screening
- •Patients that are currently taking, or have previously been treated with polyethyleneglycol3350 or tegaserod.
结局指标
主要结局
A successful outcome is defined as no longer meeting the definition of constipation using ROME I criteria
次要结局
- Analysis of individual ROME I criteria
- Safety (adverse event review)
研究者
研究点 (25)
Loading locations...
相似试验
已完成
3 期
Comparator Study of PEG 3350 Versus Prucalopride in Females With Chronic ConstipationConstipationNCT01251822Norgine240
Unknown
3 期
Efficacy and Safety of PEG 3350 for Treatment of Chronic ConstipationConstipation - FunctionalNCT03957668Fakultas Kedokteran Universitas Indonesia184
已完成
4 期
Extended Use of Polyethyleneglycol3350 Laxative in Constipated PatientsConstipationNCT00153153Braintree Laboratories300
终止
2 期
Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)Chronic Myelogenous LeukemiaNCT03547154Merck Sharp & Dohme LLC344
已完成
不适用
Enema versus high doses of PEG 3350 in the treatment of rectal fecal impaction.Childhood constipionNL-OMON23431geen90